These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28453552)

  • 41. The 3.2-Å resolution structure of human mTORC2.
    Scaiola A; Mangia F; Imseng S; Boehringer D; Berneiser K; Shimobayashi M; Stuttfeld E; Hall MN; Ban N; Maier T
    Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33158864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.
    Lee J; Shi Y; Vega M; Yang Y; Gera J; Jung ME; Lichtenstein A
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4714-4724. PubMed ID: 28916338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
    Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
    J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
    Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
    Montero JC; Chen X; Ocaña A; Pandiella A
    Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells.
    Cui Y; Zhao J; Yi L; Jiang Y
    PLoS One; 2016; 11(6):e0156915. PubMed ID: 27295037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.
    Ramaiah MJ; Kumar KR
    Mol Biol Rep; 2021 May; 48(5):4813-4835. PubMed ID: 34132942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
    Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
    Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.
    Yin Y; Hua H; Li M; Liu S; Kong Q; Shao T; Wang J; Luo Y; Wang Q; Luo T; Jiang Y
    Cell Res; 2016 Jan; 26(1):46-65. PubMed ID: 26584640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition.
    Singh BK; Sinha RA; Zhou J; Tripathi M; Ohba K; Wang ME; Astapova I; Ghosh S; Hollenberg AN; Gauthier K; Yen PM
    J Biol Chem; 2016 Jan; 291(1):198-214. PubMed ID: 26453307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
    Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
    Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein.
    Glidden EJ; Gray LG; Vemuru S; Li D; Harris TE; Mayo MW
    J Biol Chem; 2012 Jan; 287(1):581-588. PubMed ID: 22084251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
    Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
    Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.